LAVA Therapeutics’ (LVTX) Neutral Rating Reaffirmed at HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $1.50 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 16.28% from the stock’s current price.

A number of other research firms have also issued reports on LVTX. Leerink Partners restated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Stock Performance

NASDAQ LVTX opened at $1.29 on Monday. The business has a fifty day moving average price of $1.13 and a 200 day moving average price of $1.37. The company has a market cap of $33.92 million, a P/E ratio of -1.25 and a beta of 0.48. LAVA Therapeutics has a one year low of $0.85 and a one year high of $3.57.

LAVA Therapeutics (NASDAQ:LVTX) last issued its earnings results on Friday, March 28th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.18. The business had revenue of $2.50 million during the quarter, compared to analyst estimates of $2.40 million. As a group, sell-side analysts predict that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Hedge Funds Weigh In On LAVA Therapeutics

Large investors have recently modified their holdings of the business. Sanofi purchased a new stake in LAVA Therapeutics in the 4th quarter valued at about $1,825,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics during the fourth quarter valued at about $40,000. Finally, Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics in the 3rd quarter valued at approximately $32,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.